Clinical Trials Logo

Clinical Trial Summary

In this study, a multicenter, randomized, double-blind, placebo-controlled trial design is used to evaluate the efficacy and safety of two doses of 9MW1411 injection in patients with ABSSSI caused by S. aureus. The Recommended Phase 2 Dose (RP2D) of 9MW1411 injection for this placebo-controlled study is comprehensively selected based on the results of Phase I clinical trials and preclinical PK/PD analysis. Approximately 90 subjects with ABSSSI caused by S. aureus are planned to be enrolled, and the infection type and presence or absence of single S. aureus infection will be used as randomization stratification factors for all randomized subjects. They are randomized in a 1: 1: 1 ratio.


Clinical Trial Description

This study used a multicenter, randomized, double-blind, placebo-controlled trial design to evaluate the efficacy and safety of two doses of 9MW1411 injection in patients with acute staphylococcus aureus skin and skin structure infection. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05339802
Study type Interventional
Source Mabwell (Shanghai) Bioscience Co., Ltd.
Contact Shaoqing ZENG, Bachelor
Phone 021-58585793
Email shaoqing.zeng@mabwell.com
Status Recruiting
Phase Phase 2
Start date February 16, 2022
Completion date December 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Completed NCT03929224 - The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown Phase 4
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT03637400 - Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment Phase 2
Completed NCT06149117 - Bioequivalence Study of Azithromycin Capsule and Reference Formulation Sumamed * in Healthy Adult Subjects in China Phase 4
Active, not recruiting NCT05226260 - Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care N/A
Recruiting NCT03131843 - Effectiveness of Alcohol Swabs for Preventing Infections During Vaccination Phase 3
Recruiting NCT04278404 - Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Terminated NCT03372941 - Hospital Avoidance Strategies for ABSSSI Phase 4
Completed NCT02512614 - Evaluation of Novel Antimicrobial Hand Towels Phase 2/Phase 3
Completed NCT01593761 - Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus Phase 2
Not yet recruiting NCT06247761 - STASSH - TRAUMA - Absorbable vs Non-Absorbable Sutures in Trauma Hand Surgery N/A
Not yet recruiting NCT06170983 - Skin Inflammation and PK of Azithromycin N/A
Completed NCT02052388 - Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections Phase 2
Completed NCT00619710 - Complicated Skin and Skin Structure Infections Phase 3
Completed NCT06087809 - Improving Short Course Treatment for Common Pediatric Infections N/A
Not yet recruiting NCT05899140 - Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial Phase 4